Eisai Co. and Merck, known as MSD outside the United States and Canada, announced that the multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for Lenvima for the indication of unresectable HCC and the first new systemic therapy to be approved…